More than two-thirds of patients with prostate cancer have the same or even a greater survival than the general male population: a French population-based study from Francim network of cancer registries.

Date publication

décembre 2025

Journal

The French journal of urology

Auteurs

Membres identifiés du Cancéropôle Est :
Dr JOOSTE Valérie , Dr WORONOFF Anne-Sophie , Dr HAMMAS Karima

Tous les auteurs :
Lamy S, Jooste V, Delpierre C, Hammas K, Vigneron N, Woronoff AS, Coureau G, Tretarre B, Seigneurin A, Molinié F, Lapotre-Ledoux B, Systchenko T, Remontet L, Grosclaude P, Daubisse-Marliac L,

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/41386350

Résumé

Although cancer stage is a major prognostic factor, there are few studies providing population-based estimated of prostate cancer survival by stage at diagnosis, especially at a national level. Leveraging from a large sample of 10,783 cases of prostate cancer diagnosed over the period 2008-2015 from the French network of cancer registries, we provide the first estimates of prostate cancer net survival (NS) by PSA levels for mainland France. These results support that men with more advanced prostate cancers, approached by higher PSA values, had worse survival than men from the general population for the same age and geographical area. However, this group represented only 30 % of the whole cases. In the majority of cases, which are characterized by lower PSA values and probably less advanced cancer, survival rates were similar and even higher to those of men from the general population for the same age and geographical area.

Référence

Fr J Urol. 2025 12 10;:103066